Anti-Hypertensive Drugs - Finland

Finland

In Finland, the revenue in the Anti-Hypertensive Drugs market is forecasted to reach US$41.27m by the year 2024.
It is expected that the revenue will exhibit an annual growth rate (CAGR 2024-2028) of -0.44%, leading to a market volume of US$40.55m by the year 2028.
When compared on a global scale, United States is projected to generate the highest revenue in this market, amounting to US$12,290.00m in 2024.
In Finland, the demand for innovative and personalized anti-hypertensive drugs is on the rise, as the healthcare system focuses on providing effective and tailored treatment options for patients.

Key regions: Germany, United States, France, China, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in Finland has been steadily growing in recent years.

Customer preferences: Finland has a high prevalence of hypertension, which has contributed to the growth of the anti-hypertensive drugs market. Patients prefer drugs that are effective and have minimal side effects. Additionally, there is a growing preference for combination therapies that target multiple pathways to lower blood pressure.

Trends in the market: There has been a shift towards the use of generic drugs due to their lower cost. This has resulted in increased price competition among manufacturers. Additionally, there has been a rise in the use of digital health solutions such as wearables and telemedicine to monitor blood pressure and manage hypertension.

Local special circumstances: Finland has a well-developed healthcare system that provides universal access to healthcare. This has led to a high level of awareness and diagnosis of hypertension among the population. Additionally, there is a strong emphasis on preventive healthcare in Finland, which has contributed to the growth of the anti-hypertensive drugs market.

Underlying macroeconomic factors: Finland has a stable economy with a high level of healthcare spending. The government has implemented policies to promote the use of generic drugs and to control healthcare costs. Additionally, Finland has a strong pharmaceutical industry that has contributed to the growth of the anti-hypertensive drugs market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.